InMed Pharmaceuticals (INM) Net Equity Issued and Repurchased (2021 - 2023)

InMed Pharmaceuticals has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $174.0 in Q1 2023.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $174.0 in Q1 2023; TTM through Jun 2023 was $12.0 million, a 30.01% decrease from a year earlier, with the FY2023 full-year figure at $12.0 million, down 30.01% from the prior year.
• Net Equity Issued and Repurchased was $174.0 for Q1 2023 at InMed Pharmaceuticals, down from $6.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $12.0 million in Q3 2021, with the low at $174.0 in Q1 2023.
• Average Net Equity Issued and Repurchased over 3 years is $4.8 million, with a median of $5.1 million recorded in 2022.
• The largest YoY upside for Net Equity Issued and Repurchased was 3408932.39% in 2022 against a maximum downside of 50.0% in 2022.
• Over 3 years, Net Equity Issued and Repurchased stood at $176.0 in 2021, then jumped by 3408932.39% to $6.0 million in 2022, then plunged by 100.0% to $174.0 in 2023.
• The last three Net Equity Issued and Repurchased figures came in at $174.0 (Q1 2023), $6.0 million (Q4 2022), and $6.0 million (Q3 2022), per Business Quant data.